DUBLIN — Research and Markets has announced the addition of the “Prostate Cancer Vaccines and Therapeutic Antibodies: Pipeline – 2011” report to their offering.
The prostate cancer immunotherapy pipeline is showing rapid development. Currently, there are 30 candidates in the pipeline (16 vaccines and 14 therapeutic antibodies), and one prostate cancer vaccine (Provenge) has recently been approved by the FDA.
First-line treatments for prostate cancer are largely based on anti-androgen drugs, or pituitary down-regulators. Other treatments include surgery, radiotherapy and chemotherapy. Resistance is commonly seen in the case of androgen-targeting drugs. Other therapies such as surgery and radiotherapy may be effective, but present increased risk. These treatment limitations have prompted efforts to develop safer, targeted therapies.